Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to demonstrate, among patients with non-complicated CR-BSIs due to S. aureus, that a single-dose of intravenous (IV) dalbavancin 1500 mg is non-inferior to standard documented antibiotic therapy for 14 days according to national guidelines at DAY 30 (Long follow up visit). As the secondary objectives, the study aims to evaluate according to treatment group: 1. Cure rate at DAY 14 and DAY 90 (EOS); 2. Mortality rate within 90 days of follow-up; 3. Time to negativation of blood cultures; 4. Patient's quality of life; 5. Hospitalization length of stay; 6. Cost-utility analyses; 7. Occurrence of any adverse event (AE and SAE), until Day 90 (EOS).


Clinical Trial Description

Catheter-related bloodstream infections (CR-BSIs) are the most common nosocomial bloodstream infections, with an incidence as high as 8.5 to 19.8 infections per 1000 catheter-days. Staphylococcus aureus is involved in about 20% of CR-BSIs and associated with significant morbidity, mortality (9.3%), prolonged hospital stay (+ 9 days), and healthcare costs (35 000 € to 65 000 € per case). S. aureus CR-BSIs occurs mainly in frail patients with a port of catheter for chemotherapy or parenteral nutrition. According to international guidelines, management of CR-BSIs due to S. aureus includes the removal and replacement of the infected catheter and a 14-day intravenous (IV) antibiotic therapy. Therefore, the management of CR-BSIs due to S. aureus requires the insertion of a new intravenous catheter. In turn, the new catheter can also lead to new septic complications and limit the patients' autonomy. Non-adherence to these recommendations leads to over-mortality and costs. Following of the positive results of the SABATO trial in 2021 to determine whether early switch to oral antibiotic therapy is safe and effective in patients with uncomplicated BSA, oral switch during staphylococcal bacteremia, will likely become the standard of care. It is therefore justified to allow oral switch in the control arm. The usual practice in some centers is already to switch to oral antibiotics, after a minimum of 7 days of intravenous treatment. Dalbavancin is a new glycopeptide antibiotic, with an excellent bactericidal activity against Gram-positive bacteria, especially S. aureus, and a prolonged half-life of 14 to 15 days. As a comparison, half-life of antibiotics usually used for CR-BSIs due to S. aureus, i.e. penicillin or glycopeptide, as-per sensitivity to methicillin is much lower: 1.5 to 9 hours. Such prolonged half-life allows one IV injection to be sufficient and effective over 14 days of treatment. This remarkable characteristic should allow patients to be promptly discharged from hospital without monitoring. The hypothesis of the study is that in patients with CR-BSIs due to S. aureus, after catheter removal, dalbavancin could be administered intravenously in a single administration after catheter removal and be as effective as standard documented antibiotic therapy for 14 days according to national guidelines. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05117398
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Bernard CASTAN, MD
Phone +33 5 53 45 26 00
Email bernard.castan@ch-perigueux.fr
Status Recruiting
Phase Phase 3
Start date June 23, 2023
Completion date September 23, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04210505 - Nasal Decolonization of Dialysis Patients Noses Phase 4
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Completed NCT02804711 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 1
Completed NCT02282605 - Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects Phase 1/Phase 2
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2
Enrolling by invitation NCT06317688 - Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis Phase 1
Withdrawn NCT02741869 - Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients N/A
Completed NCT03966040 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 1
Completed NCT04803708 - Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers Phase 1/Phase 2
Not yet recruiting NCT06456424 - Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection Phase 1/Phase 2
Completed NCT02820883 - A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 0
Active, not recruiting NCT01879761 - Immune Resolution After Staphylococcus Aureus Bacteremia
Completed NCT01375621 - Livestock Contact and MRSA in Rural Areas
Recruiting NCT00532324 - Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in Pregnant Women and Infections in Newborns N/A
Completed NCT04503252 - Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
Recruiting NCT06368856 - Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study Phase 1
Not yet recruiting NCT05899140 - Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial Phase 4
Completed NCT01792804 - Staphylococcus Aureus Bacteremia Antibiotic Treatment Options Phase 3
Enrolling by invitation NCT04897971 - Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections
Completed NCT00572910 - A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED) Phase 2